Logo

NKGNW

NKGen Biotech, Inc. Warrants

NKGNW

NKGen Biotech, Inc. Warrants • NASDAQ
$0.03 ▲ 2408.33% (+0.03)
Market Cap $1.19 M
52w High $0.03
52w Low $0.00
Dividend Yield 0%
P/E 0
Volume 100
Outstanding Shares 205.24M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2024 $652K ▲ $5.426M ▼ $-29.414M ▼ -4.511K% ▼ $-0.84 ▼ $-15.266M ▼
Q3-2024 $0 $6.788M ▼ $6.598M ▲ 0% $0.22 ▲ $7.402M ▲
Q2-2024 $0 $7.457M ▲ $-16.088M ▼ 0% $-0.67 ▼ $-15.115M ▼
Q1-2024 $0 $7.295M ▼ $-5.382M ▲ 0% $-0.25 ▲ $-3.987M ▲
Q4-2023 $0 $9.132M $-33.606M 0% $-1.54 $-32.861M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2024 $0 ▼ $24K ▼ $0 ▼ $0 ▲
Q3-2024 $8K ▼ $14.995M ▼ $62.045M ▼ $-47.05M ▲
Q2-2024 $79K ▲ $15.648M ▼ $85.365M ▲ $-69.717M ▼
Q1-2024 $34K ▲ $16.316M ▼ $71.371M ▼ $-55.055M ▲
Q4-2023 $26K $16.481M $75.174M $-58.693M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2024 $-29.414M ▼ $-6.953M ▼ $-16K ▲ $6.967M ▲ $1.738M ▲ $-6.936M ▼
Q3-2024 $6.598M ▲ $-3.895M ▲ $-17K ▼ $3.82M ▼ $-92K ▼ $-3.912M ▲
Q2-2024 $-16.088M ▼ $-5.999M ▼ $-15K ▼ $6.059M ▲ $45K ▲ $-5.999M ▼
Q1-2024 $-5.382M ▲ $-4.034M ▲ $35K ▲ $4.007M ▲ $8K ▲ $-4.034M ▲
Q4-2023 $-33.606M $-6.939M $-18K $-1.803M $-8.76M $-6.957M

Five-Year Company Overview

Income Statement

Income Statement The company behind these warrants is still purely in the research and development phase, with no product revenue at all over the past several years. Expenses are mainly research, development, and overhead, which lead to steady operating losses each year. Losses widened meaningfully at one point, then improved somewhat more recently, but the business remains firmly loss‑making. Overall, it is a classic early‑stage biotech income statement: no sales, ongoing costs, and full dependence on outside funding to cover those losses.

Balance Sheet

Balance Sheet The balance sheet is extremely thin, reflecting a very small-scale, early-stage operation. Reported assets are minimal, and there is effectively no cash cushion visible in the data. Debt has moved around over time and, at times, equity has even been negative, which signals past accumulated losses and a fragile capital structure. In simple terms, the financial foundation is light and reliant on continued access to new capital rather than on internally generated resources.

Cash Flow

Cash Flow Cash flow is consistently negative from operations, with similar outflows year after year and no offsetting inflows from a commercial business. Free cash flow is also negative, as essentially all cash usage is tied to running and advancing the pipeline rather than to heavy investment in fixed assets. This pattern is typical for a clinical-stage biotech: the company burns cash to fund trials and must periodically raise money to extend its runway. The key risk is that, without new financing, this cash burn is not sustainable.

Competitive Edge

Competitive Edge Scientifically, the underlying company is working in a cutting-edge area of cell therapy, focusing on highly activated natural killer cells for both neurodegenerative diseases and cancer. Its approach is differentiated by using non‑genetically modified, patient‑derived cells for conditions like Alzheimer’s, with early clinical signals and a regulatory fast track that could offer a head start. Gaining full control of manufacturing and intellectual property strengthens its long‑term position and creates barriers for copycats. However, it still faces intense competition from larger, better-funded players in oncology and neurology, and its advantage will only be validated if later‑stage trial results are clearly favorable.

Innovation and R&D

Innovation and R&D Innovation is the core asset here. The company has built a proprietary platform to “super‑activate” natural killer cells, with lead programs targeting Alzheimer’s, Parkinson’s, and solid tumors. It is also exploring next‑generation technologies such as CAR‑NK cells and expanding into additional disease areas where inflammation and protein buildup are important. In‑house manufacturing capability and advanced cryopreservation techniques add practical strength to the science. Still, everything remains in the development phase: promising mechanisms and early data must survive the long, uncertain path through clinical trials and regulation.

Summary

Overall, the warrants are tied to a highly speculative, early‑stage biotech story: no revenue, ongoing losses, a thin balance sheet, and steady cash burn, offset by a scientifically ambitious and differentiated cell‑therapy platform. The company’s potential lies in its innovation around natural killer cells for hard‑to‑treat brain diseases and cancers, supported by control of its manufacturing and intellectual property. The main opportunities are successful trial results, regulatory progress, and potential partnerships; the main risks are clinical failure, financing constraints, and strong competition. This is a high‑risk, high‑uncertainty profile typical of clinical‑stage biotechnology, where outcomes depend heavily on future scientific and regulatory milestones that are not yet proven.